Hy-Sil (Sulfadiazine Silver, Sodium Hyaluronate)

Hy‑Sil is indicated for several types of superficial skin damage where infection control and a moist healing environment are desired, particularly in clinical settings.

• First‑ and second‑degree thermal burns to provide antimicrobial protection and promote re‑epithelialisation.
• Partial‑thickness skin wounds such as abrasions, donor‑site grafts, or superficial lacerations where bacterial colonisation is a concern.
• Minor dermal infections, including impetigo or localized cellulitis, caused by bacteria susceptible to sulfonamide activity.
• Post‑operative skin incisions or sutured areas with heightened infection risk, to support healing while preventing microbial growth.
• Chronic ulcerative lesions, such as pressure ulcers or venous stasis ulcers, that benefit from a moist, hyaluronic‑acid‑rich environment.

• Sulfadiazine silver releases silver ions that bind to bacterial DNA and enzymes, disrupting replication and metabolic pathways, while the sulfadiazine moiety inhibits folic‑acid synthesis in susceptible organisms. Sodium hyaluronate, a high‑molecular‑weight polysaccharide, retains water at the wound surface, creating a hydrated matrix that supports cell migration, extracellular‑matrix formation and tissue regeneration. Together, the components provide broad‑spectrum antimicrobial activity and a conducive environment for wound repair.

Topical application of Hy‑Sil may be associated with local and, rarely, systemic adverse reactions.

Common

• Mild erythema or redness at the application site.
• Pruritus or mild itching.
• Slight burning or stinging sensation during or after application.
• Dryness or peeling of the treated skin.

Serious

• Allergic contact dermatitis presenting with vesicular rash.
• Severe skin ulceration or necrosis.
• Systemic hypersensitivity reactions such as fever, chills, or malaise.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis (rare).

When using Hy‑Sil, clinicians should observe several precautionary measures to minimise risk and ensure appropriate therapy.

• Confirm absence of known sulfonamide allergy before application.
• Avoid use on deep, puncture or infected wounds that require systemic antibiotics.
• Do not apply to patients with extensive burns covering more than 20 % of body surface area without medical supervision.
• Keep the product away from eyes, mucous membranes and intact skin.
• Discontinue if signs of allergic reaction or worsening wound condition appear.
• Store at room temperature, protected from light and moisture.

Hy‑Sil can interact with certain medications or substances; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Avoid

• Concurrent systemic sulfonamide antibiotics, which may increase risk of hypersensitivity.
• Topical products containing other antimicrobial agents that could cause additive irritation.

Use with caution

• Systemic silver‑containing preparations, as cumulative silver exposure may lead to argyria.
• Corticosteroid creams applied over the same area, which may mask local reactions.
• Wound dressings that trap excess moisture, potentially enhancing systemic absorption.